capecitabine has been researched along with Cancer of Esophagus in 178 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 49 (27.53) | 29.6817 |
| 2010's | 112 (62.92) | 24.3611 |
| 2020's | 17 (9.55) | 2.80 |
| Authors | Studies |
|---|---|
| Cairns, DA; Hall, PS; Seymour, MT | 1 |
| Mizutani, T | 1 |
| Kim, DH; Wang, X; Wei, LJ | 1 |
| Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D | 1 |
| Cai, Q; Guo, L; Liu, J; Shangguan, C; Shi, M; Shi, Y; Wu, J; Xi, W; Yang, H; Zhang, J; Zhou, C | 1 |
| Bai, Y; Bei, T; Cai, M; Cai, P; Guo, Q; He, H; Huang, M; Huang, Y; Luo, G; Su, X; Wang, Z; Xiang, J; Yang, G; Zhang, X; Zheng, Y; Zhong, J | 1 |
| Derks, S; van Laarhoven, HWM | 1 |
| Ajani, JA; Amini, A; Barsoumian, HB; Bhutani, MS; Blum, MA; Chang, JY; Chen, D; Erasmus, JJ; Gomez, DR; Hess, KR; Hofstetter, WL; Lee, JH; Menon, H; Minsky, BD; Nguyen, QN; Seyedin, SN; Swisher, SG; Verma, V; Welsh, JW; Younes, AI | 1 |
| Anthoney, DA; Collins, L; Eatock, M; Elhussein, L; Falk, S; Goff, M; Lord, SR; Love, S; Middleton, MR; Moschandreas, J; Thomas, A; Turkington, RC; Virdee, PS | 1 |
| Calomino, N; Cherri, S; Farsi, M; Fiaschi, AI; Francini, E; Francini, G; Marrelli, D; Miano, ST; Petrioli, R; Rovello, F; Savelli, V; Vernillo, R | 1 |
| Feliu, J; Ghanem, I; Higuera, O; Perez-Wert, P; Rodriguez-Salas, N; Viñal, D | 1 |
| Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC | 1 |
| Alsina, M; Aranda, E; Falcó, E; Fernández, E; Galán, M; Gallego, J; García-Alfonso, P; González, E; Izquierdo-Manuel, M; Jiménez-Fonseca, P; Jorge, M; Limón, ML; López, C; López, L; Manzano, JL; Martínez de Castro, E; Muñoz-Unceta, N; Rivera, F | 1 |
| Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y | 1 |
| Al-Batran, SE; Ganguli, A; Lordick, F; Morlock, R; Sahin, U; Türeci, Ö | 1 |
| Chen, Y; Gou, H; Hu, J; Leng, W; Ni, L; Qiu, M; Zhang, W | 1 |
| Adelberg, D; Bang, YJ; Bhagia, P; Fuchs, CS; Janjigian, YY; Li, K; Qin, SK; Tabernero, J; Van Cutsem, E | 1 |
| Cho, J; Im, YH; Kang, D; Kim, K; Kim, SB; Lee, G; Na, KJ; Park, SI; Shim, YM; Yun, J; Zo, JI | 1 |
| Anderegg, MCJ; Gisbertz, SS; Hulshof, MCCM; Los, M; Mohammed, NH; Ruurda, JP; van Berge Henegouwen, MI; van der Sluis, PC; van Hillegersberg, R; van Laarhoven, HWM; van Vulpen, M; Wiezer, MJ | 1 |
| Bruns, CJ; Schröder, W | 1 |
| Anderegg, MCJ; Mohammad, NH; Ngai, LL; Ter Veer, E; Valkenhoef, GV; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Alessi, A; Battiston, C; Berenato, R; Caporale, M; Coppa, J; Cotsoglou, C; de Braud, F; Delconte, G; Di Bartolomeo, M; Fucà, G; Greco, G; Infante, G; Lazzati, S; Mazzaferro, V; Mennitto, A; Morano, F; Niger, M; Padovano, B; Pellegrinelli, A; Pietrantonio, F | 1 |
| Ahmed, M; Amir, M; Hassan, S; Khan, K; Khokhar, N; Nasir, H | 1 |
| Gong, Y; Li, GF; Yu, G | 1 |
| Chu, MP; Sawyer, MB | 1 |
| Gu, W; Shan, B; Wang, L | 1 |
| Hussaarts, KGAM; Mathijssen, RHJ; van Leeuwen, RWF | 1 |
| Boesveldt, S; de Graaf, C; de Vries, YC; Kampman, E; van Laarhoven, HWM; Winkels, RM | 1 |
| Creemers, A; de Waal, L; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Hoehler, T; Kanzler, S; Kunzmann, V; Lordick, F; Maderer, A; Meyer, HJ; Mihaljevic, AL; Moehler, M; Mönig, S; Sandermann, A; Schroll, S; Schuhmacher, C; Stahl, M; Tannapfel, A; Thuss-Patience, P; Wilke, H | 1 |
| Carter, BW; Goense, L; Ho, L; Hofstetter, WL; Lin, SH; Maru, DM; Meijer, GJ; van Hillegersberg, R; van Rossum, PSN; Xi, M | 1 |
| Hepworth, R; Smith, E; Tin, AW; Wadd, N; Walker, J; Wilson, D | 1 |
| Bhatt, L; Jackson, AS; Lavin, VJ; Mehta, S; Sheikh, HY; Sumra, P; Wang, X | 1 |
| Klaassen, R; Lambin, P; Larue, RTHM; Mearadji, B; Stoker, J; van der Woude, SO; van Laarhoven, HWM | 1 |
| Dijksterhuis, WPM; Klaassen, R; Kurk, SA; Pruijt, MJ; van der Woude, SO; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Anthoney, A; Germetaki, T; Kamposioras, K; Kordatou, Z; Mansoor, W; Nasralla, M; Owen-Holt, V; Papaxoinis, G; Stamatopoulou, S; Weaver, JMJ | 1 |
| Bowrey, DJ; Chung, WY; Dennison, AR; Eltweri, AM; Morgan, B; Thomas, AL; Thompson, J | 1 |
| Beitler, JJ; Cardin, D; Cardona, K; Chakravarthy, AB; Chen, Z; El-Rayes, BF; El-Rifai, W; Fernandez, F; Force, S; Goff, L; Harvey, RD; Higgins, K; Krasinskas, A; Lambright, E; Landry, J; Nesbitt, J; Owonikoko, T; Pickens, A; Ramalingam, SS; Saba, NF; Salaria, S; Shin, DM; Staley, C; Willingham, F | 1 |
| Ålgars, A; Kemppainen, J; Ristamäki, R; Salminen, P; Sundström, J; Vihervaara, H | 1 |
| Caballero, C; Cats, A; Elme, A; Grabsch, HI; Kang, YK; Lordick, F; Marreaud, S; Martens, U; Mauer, M; Moehler, MH; Mueller, L; Rha, SY; Thuss-Patience, P; Tokunaga, M; Wagner, AD | 1 |
| Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY | 1 |
| Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P | 1 |
| Barbachano, Y; Chau, I; Coxon, F; Crosby, T; Cunningham, D; Falk, S; Ferry, D; Frances, A; Gonzalez, D; Iveson, T; Mansoor, W; Middleton, G; Okines, AF; Okines, C; Peckitt, C; Saffery, C; Slater, S; Smith, D; Waddell, T; Wadsley, J; Waters, J; Wotherspoon, A | 1 |
| Bashir, N; Blazeby, J; Bridgewater, JA; Crosby, T; Cunningham, D; Falk, S; Geh, JI; Gollins, S; Griffiths, G; Hurt, CN; Maughan, T; Mukherjee, S; Ray, R; Roy, R; Staffurth, J | 1 |
| Bowrey, DJ; Cunnell, M; Khanna, A; Madhusudan, S; Parsons, SL; Reece-Smith, AM; Thomas, A | 1 |
| Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ | 1 |
| Arnold, D; Geissler, M; Grothe, W; Hofheinz, RD; Moehler, M; Reinacher-Schick, A; Schmoll, HJ; Seufferlein, T; Stein, A; Thuss-Patience, PC | 1 |
| Popa, EC; Shah, MA | 1 |
| Li, X; Lin, S; Lin, W; Lin, Y; Wang, H | 1 |
| Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ | 1 |
| Arena, MG; Barba, M; Belli, F; Di Lauro, L; Fattoruso, SI; Giannarelli, D; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Agterof, M; Borel-Rinkes, I; Lolkema, MP; Overkleeft, E; Reerink, O; Schipper, M; Siersema, P; Ubink, I; van der Sluis, P; van Hillegersberg, R; Vleggaar, F; Voest, E; Wijrdeman, H | 1 |
| Gonda, T; Halmos, B; Melamed, J; Miller, G; Rotterdam, H; Seetharamu, N; Villanueva, G | 1 |
| Cosson, VF; Lehle, M; Lum, BL; Ng, VW | 1 |
| Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S | 1 |
| Jiang, Z; Liang, Y; Liu, F; Song, X; Wang, W; Wu, P; Xing, L; Xu, D; Yu, X; Zang, Q; Zhang, J | 1 |
| Barham, CP; Blazeby, JM; Brookes, ST; Crosby, T; Donovan, JL; Falk, SJ; Griffin, SM; Hollingworth, W; Hollowood, AD; Krysztopik, R; Nicklin, J; Streets, CG; Strong, S; Titcomb, D; Wilson, C | 1 |
| Ahlgren, J; Akin, E; Bishop, C; Guebre-Xabiher, H; Kirkel, D; Patel, N; Schuck, S; Siegel, P; Siegel, R; Simmens, S | 1 |
| Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT | 1 |
| Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
| Boonstra, JJ; Borel Rinkes, IH; Lolkema, MP; Los, M; Ruurda, JP; Schipper, ME; Siersema, PD; Ubink, I; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Voest, EE; Wiezer, MJ | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Chen, X; Huang, X; Li, A; Song, Y; Sun, J; Wang, Z; Xu, H | 1 |
| Fisker, RV; Frøkjær, JB; Iyer, V; Kristensen, SR; Larsen, AC; Mortensen, PB; Møller, B; Thorlacius-Ussing, O; Yilmaz, MK | 1 |
| André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A | 1 |
| Bichev, D; Breithaupt, K; Daum, S; Dogan, Y; Schmidt, SC; Thuss-Patience, PC; Treese, C; von Winterfeld, M | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Berdel, WE; Brehler, AC; Hartmann, W; Kerkhoff, A; Kessler, T; Lenze, F; Palmes, D; Schliemann, C; Senninger, N; Ullerich, H; Wiebe, S | 1 |
| Li, R; Li, Y; Liu, Y; Qiao, X; Shi, G; Tan, B; Tian, Y; Wang, J; Xu, Q; Yang, P; Zhang, J; Zhao, Q | 1 |
| Calpena, R; Gallego, J; Lacueva, FJ; Martinez-Blasco, A; Mingol, F; Morcillo, MA; Moya, P; Orduña, A; Ruiz, JA; Sola-Vera, J | 1 |
| Hofheinz, RD; Lorenzen, S | 1 |
| Allum, WH; Chaudry, MA; Messager, M; Neofytou, K | 1 |
| Bronsert, P; Glatz, T; Hoeppner, J; Hopt, UT; Kulemann, B; Makowiec, F; Marjanovic, G; Schäfer, M; Sick, O; Zirlik, K | 1 |
| Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K | 1 |
| Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M | 1 |
| Azmi, S; Fadavi, H; Ferdousi, M; Malik, I; Malik, RA; Mansoor, W; Marshall, A; Petropoulos, IN; Ponirakis, G; Tavakoli, M | 1 |
| Im, YH; Kim, M; Kim, S; Lee, J; Lee, SJ; Park, SH; Park, YH | 1 |
| Barucca, V; D'Antonio, C; Falcone, R; Marchetti, P; Milano, A; Onesti, CE; Palombi, L; Righini, R; Roberto, M; Romiti, A | 1 |
| Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Legdeur, MC; Meulendijks, D; Schellens, JH | 1 |
| Bao, LB; Hua, ZL; Lu, B; Qu, CP; Sun, Z; Wang, X | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Bridgewater, J; Cunningham, D; Grenader, T; Oates, J; Peckitt, C; Starling, N; Waddell, T | 1 |
| Cooray, P; Ferraro, DA; Ganju, V; Gebski, V; Hall, M; Pavlakis, N; Price, TJ; Shannon, JA; Sjoquist, KM; Strickland, A; Tebbutt, NC; Underhill, C; Varma, SC; Veillard, AS; Wong, N; Young, R | 1 |
| Boesveldt, S; de Vries, YC; Helmich, E; Karsten, MD; van Laarhoven, HW; Winkels, RM | 1 |
| Abramovich, A; Amit, L; Brenner, B; Gordon, N; Idelevich, E; Kundel, Y; Medalia, G; Purim, O; Sadeh Gonik, U; Sarfaty, M; Sulkes, A | 1 |
| Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
| Afenjar, K; Bang, YJ; Chu, MP; Chua, N; Hecht, JR; Hiller, JP; Hoff, PM; Houe, V; Huang, YJ; Khan-Wasti, S; King, K; Koski, S; Mulder, K; Qin, S; Sawyer, MB; Scarfe, A; Slamon, D; Sobrero, A; Spratlin, J; Wainberg, ZA | 1 |
| Cho, H; Fujikawa, H; Ikeda, K; Kano, K; Maezawa, Y; Nakajima, T; Ogata, T; Sato, T; Segami, K; Yamada, T; Yoshikawa, T | 1 |
| Anthoney, A; Cheeseman, S; Collinson, M; Dent, J; Hall, PS; Howard, H; Jones, M; Last, K; Lord, SR; Lowe, C; Marshall, H; Roy, R; Seymour, MT; Swinson, D; Velikova, G | 1 |
| Banavali, S; Chougule, A; Joshi, A; Noronha, V; Patil, VM; Prabhash, K | 1 |
| Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M | 1 |
| Hang, X; Liu, C; Sun, Q; Wang, D; Zhong, B | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Chau, I; Cunningham, D; Harper, P; Hawkins, R; Hickish, T; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Seymour, M | 1 |
| An, GL; Gu, SZ; Li, XH; Lian, JW; Pan, BR; Qin, TJ; Tian, F; Zhao, XH | 1 |
| Clark, KR; Javle, MM; LeVea, C; Nava, HR; Nwogu, CE; O'Malley, L; Pendyala, L; Prey, JD; Schiff, MD; Smith, PF; Vinjamaram, S; Wilding, GE; Yang, G | 1 |
| Baselga, J; Benson, M; Cunningham, D; Hill, A; Kurek, R; Lüpfert, C; Oates, J; Rao, S; Starling, N; Wotherspoon, A | 1 |
| Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, MK; Kim, SB; Kim, YH; Lee, GH; Park, SI; Ryu, JS; Shin, JH; Song, HJ; Song, HY | 1 |
| Ahn, BM; Chae, YS; Jeon, SW; Kim, JC; Kim, JG; Lee, EB; Lee, SJ; Moon, JH; Park, IK; Sohn, SK | 1 |
| Kolluri, RB; Raouf, S; Tipples, K | 1 |
| Dinter, D; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Ströbel, P | 1 |
| Coxon, F; Cunningham, D; Daniel, F; Iveson, T; Middleton, G; Nicolson, M; Norman, AR; Oates, J; Rao, S; Starling, N | 2 |
| Allum, W; Ashley, S; Benson, M; Brown, G; Chau, I; Cunningham, D; Oates, J; Okines, A; Riddell, A; Starling, N; Stavridi, F; Thomas, J; Thompson, J; Wotherspoon, A | 1 |
| Ashley, S; Chau, I; Cunningham, D | 1 |
| Cunningham, D; Kang, YK; McCloud, P; Norman, AR; Okines, AFC | 1 |
| Balducci, M; D'Agostino, GR; Dinapoli, N; Mantini, G; Massaccesi, M; Mattiucci, GC; Meduri, B; Micciché, F; Nardone, L; Salvi, G; Valentini, V | 1 |
| Gong, HY; Huang, W; Li, BS; Li, HS; Lin, HQ; Sun, HF; Wang, LY; Wang, ZT; Wei, YM; Yi, Y; Zhang, ZC; Zhou, T | 1 |
| Saif, MW; Shi, N; Zelt, S | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Cummins, MM; Ganju, V; Gebski, V; Gibbs, D; Sourjina, T; Stockler, M; Strickland, A; Tebbutt, NC; Van Hazel, G; Zalcberg, J | 1 |
| Jørgensen, JT | 1 |
| Ashley, S; Cunningham, D; Okines, AF | 1 |
| Burris, HA; Clark, BL; Farley, C; Gray, JR; Greco, FA; Hainsworth, JD; Lane, CM; Meluch, AA; Spigel, DR | 1 |
| Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H | 1 |
| Andersen, M; Jensen, HA; Pfeiffer, P; Schønnemann, KR; Vestermark, LW; Yilmaz, M | 1 |
| Archer, C; Beadman, C; Cunningham, D; Gilligan, D; Kurek, R; Oates, J; Rao, S; Ruhstaller, T; Starling, N; Sumpter, K; Valladares-Ayerbes, M; Wilke, H | 1 |
| Aggarwal, S; Goel, G; Jauhri, M; Negi, A | 1 |
| Allali, M; Bergmann, U; Kummer, G; Riebeling, J; Schultheis, B; Sendler, A; Sendler, U; Strumberg, D; Tannapfel, A | 1 |
| Ashley, SE; Chau, I; Chua, YJ; Cunningham, D; Oates, J; Okines, AF; Saffery, C; Turner, A; Webb, J | 1 |
| Ahn, JS; Ahn, YC; Cho, EY; Im, YH; Kim, K; Kim, KH; Lee, S; Park, K; Park, YH; Shim, YM | 1 |
| Bernal, P; Byrd, J; Malik, I | 1 |
| Andersen, M; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Aklilu, M; Blackstock, AW; Clark, P; Geisinger, KR; Isom, S; Levine, EA; Mishra, G; Monjazeb, AM; Riedlinger, G | 1 |
| Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM | 1 |
| Gossage, JA; Hale, PC; Mamidanna, R; Manifold, DK; Newman, G; Pantling, AZ; Robinson, A | 1 |
| Danso-Appiah, A; Eastwood, A; Norman, G; Palmer, S; Rice, S; Spackman, E; Stirk, L; Suh, D | 1 |
| Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J | 1 |
| Abd-Ellatif, EA; El-Hadaad, HA; Wahba, HA | 1 |
| Lolkema, MP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Verhage, RJ | 1 |
| Ashley, S; Chau, I; Cunningham, D; Gujral, DM; Hawkins, MA; Leonulli, BG; Tait, D | 1 |
| Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T | 1 |
| Baglin, TP; Ford, H; Hardwick, RH; Peters, CJ; Rollins, KE; Safranek, PM | 1 |
| Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, SB; Kim, YH; Koo, DH; Lee, GH; Park, SI; Shin, JH; Song, HJ; Song, HY; Yoon, DH | 1 |
| Bellavia, T; Damodaran, S; Khushalani, NI; Sait, SN; Wang, ES; Wetzler, M | 1 |
| Abe, T; Baba, E; Boku, N; Hamamoto, Y; Hatake, K; Miyata, Y; Nishina, T; Ohashi, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamaguchi, K | 1 |
| Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI | 1 |
| Feng, XZ; Han, JQ; Sheng, W | 1 |
| Ellemann, AC; Kofoed, SC; Lundsgaard, M; Svendsen, LB | 1 |
| Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC | 1 |
| Arasaradnam, RP; Borman, RA; Goodyear, SJ; James, S; Jarvie, EM; Nwokolo, CU; Sanger, GJ; Snead, D; Sung, EZ | 1 |
| Crosby, T; Evans, M; Griffiths, G; Gwynne, S; Hurt, C; Joseph, G; Nixon, L; Spezi, E; Staffurth, J; Wills, L | 1 |
| Allum, WH; Blazeby, JM; Coxon, F; Cunningham, D; Evans, L; Falk, S; Ford, D; Griffin, M; Hall, M; Iveson, TJ; Langley, RE; Middleton, GW; Okines, AF; Petty, RD; Plummer, C; Seymour, M; Slater, S; Smith, D; Stenning, SP; Stevenson, L; Thompson, LC; Waters, J | 1 |
| Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD | 1 |
| Becker, K; Belle, S; Ebert, MP; Hofheinz, R; Krause, A; Mayr, M; Röcken, C; Schmid, RM; Schulte, N | 1 |
| Bubis, JA; Dragnev, KH; Gordon, SR; Gui, J; Lisovsky, M; Rigas, JR; Sutton, JE; Wood, MD; Zaki, BI | 1 |
| Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M | 1 |
| Hehlmann, R; Hochhaus, A; Hofheinz, RD; Weisser, A; Willer, A | 1 |
| Rich, TA; Shepard, R | 1 |
| Giglio, P; Groves, MD; Tremont-Lukats, IW | 1 |
| Chong, G; Cunningham, D | 1 |
| Cunningham, D; Harper-Wynne, C; Hickish, T; Hill, M; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Rao, S; Sumpter, K; Tebbutt, N; Ward, C | 1 |
| Bredenkamp, R; Duyster, J; Hennig, M; Lersch, C; Lordick, F; Lorenzen, S; Peschel, C; von Delius, S | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK | 1 |
| Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C | 1 |
| Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J | 1 |
| Ajani, J | 1 |
| Hengge, UR; Marini, A | 1 |
| Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D | 1 |
| Dhillon, S; Scott, LJ | 1 |
| Kang, YK | 1 |
| Holcombe, RF; Ou, SH | 1 |
| Doorn, L; Eskens, FA; van der Gaast, A; van Gameren, EC; van Meerten, E | 1 |
| Albertsson, M; Carstens, H | 1 |
| Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H | 1 |
| Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM | 1 |
| Filip, DJ; Grossniklaus, HE; Lee, WB; Sy, HM | 1 |
| Akerman, P; Berkenblit, A; Chauhan, B; Cruff, D; Evans, D; Habr, F; Harrington, D; Iannitti, D; Kennedy, T; Maia-Acuna, C; Miner, T; Safran, H; Sears, D; Stuart, K | 1 |
| Bendell, JC; Chino, JP; Clough, RW; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG | 1 |
| Ajani, JA; Cen, P | 1 |
| Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, SB; Kim, YH; Lee, GH; Lee, SS; Park, SI; Ryu, JS; Shin, JH; Song, HY | 1 |
| Borghesi, S; Hawkins, MA; Tait, D | 1 |
| Bölke, E; Budach, W; Peiper, M | 1 |
| Ben-Josef, E; Du, W; Levin, KJ; Philip, PA; Shields, AF; Vaishampayan, UN; Vaitkevicius, VK | 1 |
19 review(s) available for capecitabine and Cancer of Esophagus
| Article | Year |
|---|---|
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoplasms; Stomach Neoplasms | 2022 |
Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Male; Neoplasms; Proton Pump Inhibitors; Retrospective Studies; Stomach Neoplasms | 2020 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Proportional Hazards Models; Publication Bias; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Hand-Foot Syndrome; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Treatment Outcome; Young Adult | 2018 |
Capecitabine in the treatment of esophageal and gastric cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms | 2013 |
Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Gastrointestinal Neoplasms; Humans; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Neoplasm Metastasis; Ramucirumab; Stomach Neoplasms | 2015 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer.
Topics: Administration, Metronomic; Antineoplastic Agents; Capecitabine; Cyclophosphamide; Esophageal Neoplasms; Evidence-Based Medicine; Humans; Paclitaxel; Patient Selection; Stomach Neoplasms; Treatment Outcome | 2017 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2009 |
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome; Young Adult | 2009 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Stomach Neoplasms; Sulfonamides | 2003 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Esophageal Diseases; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms | 2006 |
Capecitabine: in advanced gastric or oesophagogastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Treatment Outcome | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
76 trial(s) available for capecitabine and Cancer of Esophagus
| Article | Year |
|---|---|
Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Topics: Capecitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local | 2023 |
SPOTlight on GLOW.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Claudins; Esophageal Neoplasms; Humans; Receptor, ErbB-2; Stomach Neoplasms | 2023 |
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Proton Therapy; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome | 2019 |
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Oxaliplatin; Perioperative Care; Receptor, ErbB-2; Spain; Stomach Neoplasms; Time Factors; Trastuzumab | 2021 |
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Claudins; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Patient Reported Outcome Measures; Progression-Free Survival; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2021 |
A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Stomach Neoplasms; Survival Rate | 2021 |
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Oxaliplatin; Randomized Controlled Trials as Topic; Response Evaluation Criteria in Solid Tumors; Stomach Neoplasms; Treatment Outcome | 2021 |
The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Staging | 2022 |
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Postoperative Care; Preoperative Care; Stomach Neoplasms | 2017 |
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Combined Modality Therapy; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Panitumumab; Perioperative Care; Prognosis; Societies, Medical; Stomach Neoplasms; Survival Rate | 2018 |
The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Proliferation; Cytokines; Dietary Supplements; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fatty Acids, Omega-3; Feasibility Studies; Female; Fish Oils; Humans; Male; Middle Aged; Oxaliplatin; Palliative Care; Pilot Projects; Prospective Studies; Stomach Neoplasms; Treatment Outcome; Triglycerides | 2019 |
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Prognosis; Prospective Studies | 2019 |
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Perioperative Period; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Stomach Neoplasms; Trastuzumab; Treatment Outcome; Young Adult | 2019 |
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex | 2013 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Protein Kinase Inhibitors; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Vomiting | 2013 |
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Taxoids | 2013 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Perioperative Care; Preoperative Care; Prospective Studies; Survivors | 2014 |
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Young Adult | 2014 |
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2015 |
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Pilot Projects; Treatment Outcome | 2014 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Stomach Neoplasms; Survival Rate | 2015 |
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Receptor, ErbB-2; Stomach Neoplasms | 2015 |
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult | 2015 |
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Retreatment; Treatment Outcome | 2015 |
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Genetic Predisposition to Disease; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Efficacy and safety of capecitabine as maintenance therapy after capecitabine-based combination chemotherapy for patients with advanced esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Hematologic Diseases; Humans; Male; Middle Aged; Nausea; Treatment Outcome | 2015 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoadjuvant Therapy; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Stomach Neoplasms | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Fluorouracil; Humans; Infections; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Panitumumab; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2016 |
A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids | 2016 |
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Interactions; Esophageal Neoplasms; Female; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proton Pump Inhibitors; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2017 |
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Frail Elderly; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Palliative Care | 2017 |
Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Deoxycytidine; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboxylesterase; Combined Modality Therapy; Cytidine Deaminase; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thymidine Phosphorylase | 2009 |
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2008 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Survival Rate; Treatment Outcome | 2009 |
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Thromboembolism; United Kingdom; Warfarin | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 2009 |
Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Rate | 2009 |
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome; United States | 2010 |
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Outpatients; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2010 |
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Stomach Neoplasms | 2010 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Vomiting | 2010 |
Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2012 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2011 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Time Factors | 2012 |
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2012 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Rate | 2011 |
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Observer Variation; Quality Assurance, Health Care; Radiography; Tumor Burden | 2012 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Stomach Neoplasms; Stroke Volume; Thromboembolism; Treatment Outcome | 2013 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiovascular Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Recombinant Fusion Proteins; Stomach Neoplasms; Treatment Outcome; Young Adult | 2013 |
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms | 2012 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom | 2002 |
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2005 |
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids | 2005 |
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardia; Deoxycytidine; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage | 2007 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Stomach Neoplasms; Survival Analysis | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase | 2008 |
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids | 2007 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Quality of Life; Stomach Neoplasms; Survival Rate | 2008 |
83 other study(ies) available for capecitabine and Cancer of Esophagus
| Article | Year |
|---|---|
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population-Reply.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Oxaliplatin; Stomach Neoplasms | 2021 |
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Oxaliplatin; Stomach Neoplasms | 2021 |
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Oxaliplatin; Stomach Neoplasms | 2021 |
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Docetaxel; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Perioperative Care; Propensity Score; Stomach Neoplasms; Treatment Outcome | 2022 |
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Esophageal Neoplasms; Esophagogastric Junction; Exanthema; Fatigue; Female; Humans; Male; Margins of Excision; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Stomach Neoplasms; Vomiting | 2020 |
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prospective Studies; Stomach Neoplasms | 2020 |
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Hospital Mortality; Humans; Length of Stay; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Postoperative Complications; Propensity Score; Survival Rate; Treatment Outcome | 2020 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pyridines; Retrospective Studies; Tegafur | 2021 |
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Perioperative Care; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2017 |
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin | 2017 |
Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor.
Topics: Antineoplastic Agents; Biopsy; Capecitabine; Carcinoma; Cisplatin; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Humans; Immunohistochemistry; Middle Aged; Treatment Outcome | 2017 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer-Reply.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Low reported taste function is associated with low preference for high protein products in advanced oesophagogastric cancer patients undergoing palliative chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Dietary Proteins; Esophageal Neoplasms; Female; Food Preferences; Humans; Male; Middle Aged; Oxaliplatin; Palliative Care; Stomach Neoplasms; Taste | 2019 |
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Nomograms; Oxaliplatin; Positron Emission Tomography Computed Tomography; Preoperative Period; Radiopharmaceuticals; Radiotherapy Dosage; Risk Assessment; Sex Factors; Survival Rate | 2018 |
Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2018 |
Experience of Definitive Chemoradiation for Oesophageal Cancer Within a Large Regional Cancer Treatment Centre: Improving Outcomes and Tolerability.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate | 2018 |
Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients.
Topics: Adult; Aged; Capecitabine; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Predictive Value of Tests; Retrospective Studies; Stomach Neoplasms; Tomography, X-Ray Computed | 2018 |
Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Obesity; Oxaliplatin; Palliative Care; Sarcopenia; Stomach Neoplasms | 2019 |
The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Perioperative Period; Propensity Score; Retrospective Studies; Survival Rate | 2019 |
Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Oxaliplatin; Perioperative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2019 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Catheterization, Peripheral; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Perioperative Period; Pulmonary Embolism; Retrospective Studies; Stomach Neoplasms; Survival Rate; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2014 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom | 2014 |
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies | 2014 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Haptoglobins; Hematologic Diseases; Hemolytic-Uremic Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2014 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Sarcopenia; Stomach Neoplasms; Tomography, X-Ray Computed | 2015 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Retrospective Studies; Safety; Stomach Neoplasms; Survival Rate; Time Factors | 2015 |
Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer--a clinical prospective study of outcome and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Female; Humans; Incidence; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Prospective Studies; Pulmonary Embolism; Recurrence; Risk Factors; Stomach Neoplasms; Treatment Outcome; Venous Thrombosis | 2015 |
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2015 |
High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Perioperative Period; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Analysis | 2015 |
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platelet Count; Preoperative Period; Prognosis; Retrospective Studies; ROC Curve; Survival Rate | 2015 |
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced Peripheral Neuropathy.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cold Temperature; Cornea; Epirubicin; Erythromelalgia; Esophageal Neoplasms; Female; Hot Temperature; Humans; Hyperalgesia; Liver Neoplasms; Male; Microscopy, Confocal; Middle Aged; Nerve Fibers; Nerve Regeneration; Neural Conduction; Organoplatinum Compounds; Oxaliplatin; Pain Threshold; Stomach Neoplasms; Trastuzumab; Vibration | 2015 |
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Upper Gastrointestinal Tract | 2016 |
The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study.
Topics: Aged; Antineoplastic Agents; Capecitabine; Cross-Sectional Studies; Esophageal Neoplasms; Female; Food Preferences; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Qualitative Research; Stomach Neoplasms | 2016 |
[A Case of HER2-Positive Siewert Type I Adenocarcinoma of the Esophagogastric Junction Treated via Neoadjuvant Chemotherapy Followed by Radical Resection].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Trastuzumab; Treatment Outcome | 2016 |
The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Stomach Neoplasms; United Kingdom | 2017 |
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism | 2017 |
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leukopenia; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Patient Selection; Prognosis; Survival Analysis; Time Factors | 2009 |
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Survival Analysis | 2009 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes | 2009 |
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fatal Outcome; Fluorouracil; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Oxaloacetates; Time Factors; Treatment Outcome | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Palliative Care; Pemetrexed; Prospective Studies; Radiation Tolerance; Radiotherapy Dosage; Young Adult | 2010 |
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Insurance, Health, Reimbursement; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; United States | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2010 |
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids | 2010 |
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Denmark; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fever; Fluorouracil; Humans; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Contrast Media; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome | 2010 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Weight Loss | 2011 |
Outcomes from chemoradiotherapy for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome | 2011 |
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Prospective Studies; Risk Factors; Thromboembolism | 2012 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Gastrectomy; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Risk Factors; Stomach Neoplasms; Venous Thromboembolism | 2011 |
Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer.
Topics: Abnormal Karyotype; Adenocarcinoma; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Radiotherapy; Translocation, Genetic | 2012 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2012 |
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabine; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Deglutition Disorders; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Perforation; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prosthesis Failure; Retrospective Studies; Stents; Taxoids | 2012 |
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbachol; Chemotherapy, Adjuvant; Cholinergic Agonists; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Ganglia, Autonomic; Gastric Emptying; Gastric Mucosa; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Neoadjuvant Therapy; Stomach; Stomach Neoplasms | 2012 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Thoracic Neoplasms; Tomography, X-Ray Computed | 2013 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Activation; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Thymidine Phosphorylase; Treatment Outcome | 2003 |
Response of neoplastic meningitis from solid tumors to oral capecitabine.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Ductal, Breast; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningitis; Middle Aged; Prodrugs | 2003 |
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2005 |
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2006 |
[Hand-foot syndrome with capecitabine therapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Localized; Syndrome | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Thymidine Phosphorylase | 2007 |
Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Humans; Male; Treatment Outcome | 2007 |
Metastatic esophageal adenocarcinoma presenting in the iris.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Iris Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2007 |
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies | 2007 |
Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis | 2007 |
Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Costs; Esophageal Neoplasms; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2008 |
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis | 2002 |